Status:
WITHDRAWN
Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
Lead Sponsor:
Ache Laboratorios Farmaceuticos S.A.
Conditions:
Inflammation
Cough
Eligibility:
All Genders
2-12 years
Phase:
PHASE3
Brief Summary
Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-product...
Eligibility Criteria
Inclusion
- Patients between 2 and 12 years old, of both sexes;
- Clinical condition compatible with acute rhinitis accompanied by nasal obstruction;
- Non-productive cough, daytime and/or nighttime with at least 3 and up 5 consecutive days in duration;
- Score greater than or equal to 3 points on the cough severity score (As per item 4.1.2);
- Score greater than or equal to 2 points on the nasal obstruction severity score (As per item 4.1.3);
- ICF signed by a parent/caregiver/representant;
- Parent/Caregiver/Representant capacity, according to investigator evaluation, for compliance at the treatment and protocol requirements, fulfilling the regular visits;
Exclusion
- Non-productive cough with purulent smear, fever (axillar temperature superior than 37,8°C/100°F), purulent runny nose and other signs and symptoms of bacteria infection of upper and lower airways at 7 days before the screening/randomization visit;
- Septal deviation level III (in any region and any nasal cavity) and/or nasal polyps or other determinants conditions of nasal congestion;
- Previous diagnosis of asthma;
- Patients under treatment for chronic allergy;
- Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;
- Current use of systemic antibiotics for any reason;
- Use of prohibited medicine within the prescribed period before V0 as shown in item 9.3 of this protocol;
- Participation in last one year of clinical protocols;
- Any psychiatric diseases, including major depression;
- Presence of mental retardation from any cause;
- Diagnosis of renal or hepatic failure;
- History of hypersensitivity to any component of the study drugs;
- Relatives of sponsor´s or study site´s employee;
- Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation;
- Patient or parent/caregiver/representant with a history of lack of compliance to treatment or previous treatment protocols;
- Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01177852
Start Date
October 1 2011
Last Update
October 19 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.